News Sentiment

MLTX sentiment intelligence

MoonLake Immunotherapeutics news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 20.36 Week of 10 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

85/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+7.4% over one week, +8.9% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

Jerucon plans 150,000-share MLTX sale in Form 144 (Nasdaq: MLTX)

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 85/100 classification
One-week reaction 7.4% Price confirming higher
Trend fit Trend active 8.9% over four weeks
Fair value -49.3% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 39
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 17
Market source 10
TradingView 5
simplywall.st 5
Stocktwits 3
The National Law Review 2
MT Newswires 2
Quiver Quantitative 2

Event Lens

What the news is about

Classified themes
Market update 41
Earnings 13
Regulatory and legal 3
Guidance 1
Deals and strategy 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 60
Stock Titan Direct company coverage

MoonLake Immunotherapeutics (NASDAQ: MLTX) raises $30M via option exercise

MoonLake Immunotherapeutics announced that underwriters fully exercised their option to purchase an additional 1,500,000 Class A ordinary shares as part of a previously announced public offering. This exercise, which closed on July 14, 2026, generated an additional $30.0 million

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 10:11
Source
Stock Titan
Stock Titan Direct company coverage

[Form 4] MoonLake Immunotherapeutics Insider Trading Activity

MoonLake Immunotherapeutics CEO Jorge Santos da Silva sold 102,225 Class A ordinary shares in open market transactions on July 9 and 10, 2026. The sales, totaling approximately $2.05 million, were made under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, S

Tone
Negative 39/100
Event
Market update
Published
13 Jul 2026 19:42
Source
Stock Titan
Stock Titan Direct company coverage

CEO of MoonLake Immunotherapeutics (NASDAQ: MLTX) sells shares under plan

The CEO of MoonLake Immunotherapeutics (NASDAQ: MLTX), Jorge Santos da Silva, sold 47,775 Class A ordinary shares at a weighted average price of $20.03 per share on July 1, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 31, 202

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 16:39
Source
Stock Titan
The National Law Review Direct company coverage

Class Action Lawsuit Filed Against MoonLake Immunotherapeutics (MLTX) – Recover Losses - Contact Levi & Korsinsky Before December 15, 2025

A class action lawsuit has been filed against MoonLake Immunotherapeutics (MLTX) by Levi & Korsinsky, LLP, seeking to recover losses for shareholders affected by alleged securities fraud between March 10, 2024, and September 29, 2025. The lawsuit claims that the company made fals

Tone
Negative 5/100
Event
Regulatory and legal
Published
02 Jul 2026 12:40
Source
The National Law Review
Stock Titan Direct company coverage

MLTX (Nasdaq) Rule 144 notice shows 150,000 Class A shares sale (04/10/2026)

MoonLake Immunotherapeutics (MLTX) has filed a Rule 144 notice indicating a proposed resale of 150,000 Class A Ordinary shares. The filing specifies a contemporaneous sale of these shares by Jorge Santos da Silva on April 10, 2026, for $2,787,000.00. The shares are listed on Nasd

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 15:11
Source
Stock Titan
Stock Titan Direct company coverage

BVF group reports 19.7% MoonLake Immunotherapeutics (MLTX) stake

BVF group has updated its ownership disclosure in MoonLake Immunotherapeutics (MLTX) through an Amendment No. 6 to its Schedule 13D. The filing indicates that BVF-affiliated funds beneficially own 16,001,284 Class A ordinary shares, representing approximately 19.7% of MoonLake's

Tone
Neutral 50/100
Event
Deals and strategy
Published
30 Jun 2026 03:09
Source
Stock Titan
Sahm Direct company coverage

MoonLake Immunotherapeutics (MLTX) Is Down 10.2% After $200M Follow-On Offering To Fund Sonelokimab Push - Has The Bull Case Changed?

MoonLake Immunotherapeutics (MLTX) recently raised $200 million through a follow-on equity offering to fund its sonelokimab program, particularly for the planned Biologics License Application (BLA) in hidradenitis suppurativa and pre-commercial activities. This capital raise, fol

Tone
Negative 39/100
Event
Market update
Published
29 Jun 2026 17:09
Source
Sahm
Global Legal Chronicle Direct company coverage

MoonLake Immunotherapeutics Completes $200 Million Public Offering of Class A Shares

MoonLake Immunotherapeutics (NASDAQ: MLTX) has successfully completed a $200 million public offering of its Class A shares. The offering involved legal advisory from Gibson, Dunn & Crutcher LLP and Walkers (Cayman) LLP for MoonLake, while Mintz, Levin, Cohn, Ferris, Glovsky, and

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 14:39
Source
Global Legal Chronicle
The National Law Review Direct company coverage

Lost Money on MoonLake Immunotherapeutics (MLTX)? Join Class Acti

Levi & Korsinsky LLP has filed a class action securities lawsuit against MoonLake Immunotherapeutics (MLTX) for alleged securities fraud between March 10, 2024, and September 29, 2025. The lawsuit claims that the company made false statements about the purported superiority of it

Tone
Negative 10/100
Event
Regulatory and legal
Published
28 Jun 2026 17:10
Source
The National Law Review
TradingView Direct company coverage

MoonLake Immunotherapeutics Class A Actuals & Estimates (NASDAQ:MLTX)

This article provides an overview of MoonLake Immunotherapeutics (NASDAQ: MLTX) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It also details financial information such as past earnings and revenue, upcoming earnings dat

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 04:09
Source
TradingView
Mondaq Direct company coverage

United States - Mintz Advises On MoonLake Immunotherapeutics’ $200 Million Public Offering

Mintz advised the underwriters for MoonLake Immunotherapeutics' $200 million public offering of Class A ordinary shares. Leerink Partners, Guggenheim Securities, Cantor, and LifeSci Capital served as joint bookrunning managers, with H.C. Wainwright & Co. and Clear Street as lead

Tone
Positive 72/100
Event
Market update
Published
26 Jun 2026 03:41
Source
Mondaq
TradingView Direct company coverage

MoonLake Immunotherapeutics Class A Actuals & Estimates (BOATS:MLTX)

This article provides an overview of MoonLake Immunotherapeutics (MLTX) stock, including financial actuals and analyst estimates. It details the company's valuation metrics, past financial performance, future earnings projections, and historical stock prices. Key financial figure

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 01:09
Source
TradingView
TradingView Direct company coverage

MoonLake Immunotherapeutics Class A Actuals & Estimates (BIVA:MLTX/N)

This article provides financial actuals and estimates for MoonLake Immunotherapeutics Class A (MLTX/N) traded on BIVA exchange, including market cap, earnings reports, revenue, and net income. It also details analysts' price targets, stock volatility, and employees. The company's

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 00:41
Source
TradingView
TradingView Direct company coverage

MLTX/N Forecast — Price Target — Prediction for 2027

This article provides a forecast for MoonLake Immunotherapeutics Class A (MLTX/N) stock, including analyst price targets, ratings, and financial metrics. It highlights that 14 analysts offer 1-year price forecasts, and outlines the company's past earnings, revenue, and market cap

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 18:41
Source
TradingView
Market source Direct company coverage

MoonLake Immunotherapeutics Announces Proposed Public Offering

MoonLake Immunotherapeutics has announced a proposed public offering of $150 million of its Class A ordinary shares, and potentially pre-funded warrants, to fund the development and commercialization of its investigational drug sonelokimab. The company also expects to grant under

Tone
Neutral 50/100
Event
Regulatory and legal
Published
25 Jun 2026 03:39
Source
Market source